argenx SE (ARGX)

NASDAQ: ARGX · USD

$872

-16.62 (-1.9%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-07-29 02:00 UTC. Latest published research analyzed 2026-05-20 · stale · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh ARGX analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-20

Our latest published analysis: ARGX rated Strong Buy

Strong Buy based on durable hyper-growth and multiple secondary indications.

Fair value (mid)

$1,486 / share

$654 – $2,709

Upside to FV

+86.3%

from $872

Confidence

82/100

Moat

6.5/10

Read full analysis →

Market cap	$49.9B
Revenue (ttm)	5.3B
Net income (ttm)	1.7B
EPS (ttm)	$26.2
Shares out	62.5M
P/E (trailing)	32.1x
P/E (forward)	21.8x
Volume	293,941
Beta	-0.02
Price target	$1,080	+23.8%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 5.3B
Net income (ttm): 1.7B
EPS (ttm): $26.2
P/E (trailing): 32.1x
P/E (forward): 21.8x
Market cap: $49.9B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$410.7M	$1.23B	$2.19B	$4.15B	+116.2%
Gross profit	$381.3M	$1.11B	$1.96B	$3.70B	+113.3%
Operating income	$-723.9M	$-420.6M	$-17.8M	$1.05B	—
Net income	$-709.6M	$-295.1M	$833.0M	$1.29B	—
EPS (diluted)	$-13.05	$-5.16	$12.78	$19.57	—
EBITDA	$-622.8M	$-192.3M	$105.2M	$1.31B	—
R&D	$663.4M	$859.5M	$983.4M	$1.36B	+27.2%
SG&A	$469.9M	$709.5M	$1.05B	$1.36B	+42.5%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.5B	73.0x	9.0x	78.4%	+49.7%	-12.3%	Strong Buy
ANET	Arista Networks Inc.	213.7B	58.7x	22.0x	237.4%	+31.6%	+48.5%	Strong Buy
DDOG	Datadog Inc.	89.3B	657.7x	24.3x	-3.7%	+40.5%	+67.4%	Sell
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold
SNY	Sanofi	108.7B	12.5x	2.0x	9.4%	+5.1%	-6.0%	Buy

All ARGX indicators

Market & fundamental data

Available fields

242

Groups with data

Currency

USD

Showing 242 of 242 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001697862
Company name	argenx SE
Country	Netherlands
Country code	US
Cusip	04016X101
Employees	1,863
Employees Change	264%
Employees Change Percent	16.51
Enterprise value	$49.9B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2017-05-18
Isin	US04016X1019
Last refreshed	2026-07-29
Market cap	$55B
Market cap category	Large-Cap
Price	$872
Price currency	USD
Rev Per Employee	2,853,177.13x
Sector	Healthcare
Sector PE	45.13
Sector PE Fwd	23.9
Sic	2836
Symbol	ARGX
Website	https://argenx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.12%
EV Earnings	29.09x
EV Sales Forward	7.07x
EV/EBIT	31.15x
EV/EBITDA	30.54x
EV/FCF	51.43x
EV/Sales	9.39x
FCF yield	1.76%
Forward P/E	25.5x
P/B ratio	6.54x
P/E ratio	32.08x
P/S ratio	10.35x
PS Forward	7.79x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	30.06%
EBITDA Margin	30.66%
FCF margin	18.25%
Gross margin	59.07%
Gross Profit	$3.1B
Gross Profit Growth	93.52%
Gross Profit Growth Q	73.83%
Gross Profit Growth3 Y	407.57%
Gross Profit Growth5 Y	113.52%
Net Income	$1.7B
Net Income Growth	33.93%
Net Income Growth Q	92.24%
Net Income Growth Years	3%
Pretax Margin	32.86%
Profit Margin	32.26%
Profit Per Employee	$920,577
Profitable Years	2
ROA	11.63
Roa5y	-4.42
ROCE	18.94
ROE	23.63
Roe5y	-3.39
ROIC	50.65

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	47.38%
Cagr3y	19.66%
Cagr5y	23.71%
EPS Growth	39.82
EPS Growth Q	95.17
EPS Growth Years	3
FCF Growth	143.78%
OCF Growth	141.19%
OCF Growth10 Y	51.21%
Revenue Growth	70.3x
Revenue Growth Q	59.26x
Revenue Growth Years	0x
Revenue Growth3 Y	85.31x
Revenue Growth5 Y	58.8x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.62
Assets	$10B
Cash	$5.2B
Current Assets	$8.1B
Current Liabilities	$1.6B
Debt	$47M
Debt EBITDA	$0.03
Debt Equity	$0.01
Debt FCF	$0.05
Equity	$8.4B
Interest Coverage	504.5
Liabilities	$1.6B
Long Term Assets	$2B
Long Term Liabilities	$40M
Net Cash	$5.1B
Net Cash By Market Cap	$9.34
Net Cash Growth	32.23%
Net Debt EBITDA	$-3.14
Net Debt Equity	$-0.61
Net Debt FCF	$-5.3
Tangible Book Value	$8.2B
Tangible Book Value Per Share	$130
WACC	4.13

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.12
Inventory Turnover	6.12
Net Working Capital	$1.3B
Quick ratio	4.52
Working Capital	$6.5B
Working Capital Turnover	$0.94

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	4.24%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	47.34%
200-day SMA	829
3Y total return	71.35%
50-day SMA	867
50-day SMA vs 200-day SMA	50over200
5Y total return	189.72%
All Time High	953.6
All Time High Change	-8.53%
All Time High Date	2026-07-02
All Time Low	17.33
All Time Low Change	4,933.06%
All Time Low Date	2017-05-18
ATR	29.79
Beta	-0.02
Ch YTD	3.72
High	895.6
High52	953.6
High52 Date	2026-07-02
High52ch	-8.53%
Low	870
Low52	590.8
Low52 Date	2025-07-29
Low52ch	47.64%
Ma50ch	0.6%
Premarket Change Percent	-0.3
Premarket Price	$886
Premarket Volume	307
Price vs 200-day SMA	5.21%
RSI	48.39
RSI Monthly	63.67
RSI Weekly	56.09
Sharpe ratio	1.23x
Sortino ratio	2.23
Total Return	4.24%
Tr YTD	3.72
Tr1m	-1.69%
Tr1w	-0.29%
Tr3m	11.29%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	24
Analyst Count Top	14
Analyst Price Target Top	$1,087
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$5.56
Earnings EPS Estimate Growth	48.66
Earnings Revenue Estimate	1,289,160,200x
Earnings Revenue Estimate Growth	33.29x
Operating Income	$1.6B
Operating Income Growth	249.9
Operating Income Growth Q	148
Operating margin	30.13
Price target	$1,080
Price Target Change	$23.77
Price Target Change Top	$24.66

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	62,426,019%
Float Percent	99.82%
Net Borrowing	-10,107,000
Shares Insiders	0.18%
Shares Institutions	78.33%
Shares Out	62,537,923
Shares Qo Q	-2.76%
Shares Yo Y	-4.24%
Short Ratio	4.14
Short Shares	2.46

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$715.9M
Adjusted OCF	720,113,000
Average Volume	306,857.85x
Bv Per Share	134.6
CAPEX	$-4.2M
Ch1m	-1.69
Ch1w	-0.29
Ch1y	47.34
Ch3m	11.29
Ch3y	71.35
Ch5y	189.7
Ch6m	0.9
Change	-1.87%
Change From Open	-1.84
Close	888.8
Days Gap	-0.02
Depreciation Amortization	11,287,000
Dollar Volume	256,384,158.4
Earnings Date	2026-07-23
Earnings Time	bmo
EBIT	$1.6B
EBITDA	$1.6B
EPS	$26.21
F Score	5
FCF	$970M
FCF EV Yield	1.94x
FCF Per Share	$15.51
Financing CF	264,010,000
Fiscal Year End	December
Founded	2,008
Graham Number	285.74148
Graham Upside	-67.24
Income Tax	$31.6M
Investing CF	264,005,000
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-07-23
Last Report Date	2026-06-30
Last Split Type	Never
Last10k Filing Date	2026-03-19
Ma150	816.9
Ma150ch	6.78%
Ma20	890.5
Ma20ch	-2.05%
Net CF	1,498,353,000
Next Earnings Date	2026-10-29
Open	888.6
Optionable	Yes
P FCF Ratio	56.71
P FCF Ratio SBC	76.84
P OCF Ratio	56.47
P OCF Ratio SBC	76.39
Position In Range	8.72
Post Close	872.2
Postmarket Change Percent	1.2
Postmarket Price	$883
Ppne	52,000,000
Pre Close	888.8
Price Date	2026-07-28
Price EBITDA	$33.68
Ptbv Ratio	6.75
Relative Volume	0.96x
Revenue	5,315,469,000x
SBC By Revenue	4.78x
Share Based Comp	254,079,000
Tax By Revenue	0.59x
Tax Rate	1.81%
Tr6m	0.9%
Volume	293,941
Z Score	19.76

Frequently asked questions

About this ARGX report

What is the latest published ARGX stock rating?

argenx SE is shown with strong buy in the latest published report, analyzed 2026-05-20. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ARGX analysis?

The full latest published report, analyzed 2026-05-20, lives at /stocks/ARGX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for ARGX?

The latest published report analyzed 2026-05-20 frames ARGX around USD 654 to USD 2,709. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the ARGX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-20). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

argenx SE (ARGX)

Coverage state: Latest published research available

Generate a fresh ARGX analysis

Our latest published analysis: ARGX rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · ARGX

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All ARGX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ARGX

Frequently asked questions